Ranitidine ban deferred despite cancer concerns

Despite concerns about cancer-causing agents in Ranitidine and an expert panel's recommendation to suspend it, India's drug advisory body has decided to form another committee to investigate. Previous tests revealed that many Ranitidine samples contained unsafe levels of NDMA impurities. The ICMR has been asked to conduct a study to assess the drug's safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/26VQDur
via IFTTT

Read More

BDR Pharmaceuticals plans $100 mn expansion in the US with manufacturing buyouts

BDR Pharmaceuticals is set to broaden its presence in the US through acquisitions of manufacturing facilities, backed by a $100 million investment. Chairman Dharmesh Shah mentioned the company is evaluating potential units and expects a decision within months, funded by internal accruals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cK9xTlR
via IFTTT

Read More

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India through share swap

Aster DM Healthcare has finalized the acquisition of a 5% stake in Quality Care India Ltd (QCIL) through a share swap with BCP Asia II TopCo IV Pte Ltd and Centella Mauritius Holdings Limited. This acquisition marks the initial phase of the strategic merger between Aster DM Healthcare and Quality Care India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L2kfr6d
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod for generic cholesterol lowering drug

Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, 750 mg, and 1,000 mg strengths. These tablets, produced in Ahmedabad, address elevated cholesterol and triglycerides, reducing the risk of myocardial infarction. The US market for these tablets has annual sales of USD 5.5 million, according to IQVIA MAT February 2025 data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JsOMtPg
via IFTTT

Read More

Max Healthcare lines up Rs 6,000 crore for expansion

Max Healthcare is set to invest ₹6,000 crore over the next three years to expand its network, aiming to reach 25 hospitals by 2025. The expansion includes new facilities in Saket, Nanavati, Mohali, and Gurugram, with a recent inauguration of a 300-bed hospital in Dwarka.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pnvJMtA
via IFTTT

Read More

Max Healthcare Institute to invest Rs 6,000 cr to add 3,700 beds by 2028

Max Healthcare will invest Rs 6,000 crore by 2028 to add 3,700 beds across India, increasing its facilities to around 30 hospitals. The expansion, funded internally, includes the recent inauguration of a 300-bed hospital in Dwarka, Delhi, and upcoming facilities in Mohali, Mumbai, and Saket. The company remains open to acquisitions beyond its organic growth plans.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r215cM9
via IFTTT

Read More

Medanta to invest Rs 500 cr to set up 400-bed hospital in Guwahati

Global Health, known for its Medanta hospitals, is set to invest approximately Rs 500 crore in establishing a 400-bed super speciality hospital in Guwahati, Assam. The board has approved the land purchase for Rs 30 crore. This initiative aims to enhance healthcare infrastructure, offering advanced medical care across 20 specialities to over 50 million people in Assam and neighboring states.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Tx8vSez
via IFTTT

Read More